Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.

Bioinformatics (Oxford, England) - 1 Sept 2014

Kim Jihye, Vasu Vihas T, Mishra Rangnath, Singleton Katherine R, Yoo Minjae, Leach Sonia M, Farias-Hesson Eveline, Mason Robert J, Kang Jaewoo, Ramamoorthy Preveen, Kern Jeffrey A, Heasley Lynn E, Finigan James H, Tan Aik Choon

Abstract excerpt

MOTIVATION: Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death in the United States. Targeted tyrosine kinase inhibitors (TKIs) directed against the epidermal growth factor receptor (EGFR) have been widely and successfully used in treating NSCLC patients with activating EGFR mutations. Unfortunately, the duration of response is short-lived, and all patients eventually relapse by acquiring...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Nitriles

Share to Protein Kinases

Share to Quinazolines

Share to Quinolines

Share to Sequence Analysis, RNA

Source

Open in PubMed Open full text

Identifiers

PMID: 24812339
DOI: 10.1093/bioinformatics/btu323
PMCID: PMC4147888

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.PMID 24812339Read ↗

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.Semantic proximity Read ↗

Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer.Semantic proximity Read ↗

Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.Semantic proximity Read ↗

Knowledge Graph-based Recommendation Framework Identifies Novel Drivers of Resistance in EGFR mutant Non-small Cell Lung CancerSemantic proximity Read ↗

Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data.Semantic proximity Read ↗

Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors.Semantic proximity Read ↗

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.Semantic proximity Read ↗

Combined kinome inhibition states are predictive of cancer cell line sensitivity to kinase inhibitor combination therapiesSemantic proximity Read ↗

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.Semantic proximity Read ↗

Global proteome and phosphoproteome alterations in third generation EGFR TKI resistance reveal drug targets to circumvent resistanceSemantic proximity Read ↗

Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects.Semantic proximity Read ↗

An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.